Compare CRESY & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | CSTL |
|---|---|---|
| Founded | 1936 | 2007 |
| Country | Argentina | United States |
| Employees | 2889 | N/A |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.3M | 722.8M |
| IPO Year | N/A | 2019 |
| Metric | CRESY | CSTL |
|---|---|---|
| Price | $10.91 | $31.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 239.9K | ★ 390.6K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.14% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $2.42 |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $8.39 | $17.72 |
| 52 Week High | $14.21 | $44.28 |
| Indicator | CRESY | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 74.87 |
| Support Level | $11.12 | $22.67 |
| Resistance Level | $11.84 | $34.97 |
| Average True Range (ATR) | 0.39 | 1.45 |
| MACD | 0.03 | 0.55 |
| Stochastic Oscillator | 60.77 | 89.62 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.